Dr. Javier Weber

Pathologist · Osaka University Hospital · Japan (JP) · Oncology

Tier 3STK-0007GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC
Scientific interests: irAE management
Engagement preference: Virtual
Advisory boards: 1
Publications: 4
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 30 Apr 2026 (138 days ago)
Next planned contact: 30 Apr 2027
Last 6 months vs target: 100%
1 of 1 expected engagements

Insights from this stakeholder (1)

INS-0064PD-L1 testing turnaround
30 Apr 2026 · Evidence gap
HighAction in progress

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
30 Apr 2026	Scientific exchange	Phone	James Whitfield	Vantrexa	PD-L1 testing turnaroundElderly / ECOG 2 patients	1	—	Reviewed	ENG-0056

Timeline

30 Apr 2026
Scientific exchange
PD-L1 testing turnaround, Elderly / ECOG 2 patients

Related stakeholders (9)

Osaka University Hospital

Dr. Noor Dubois
Thoracic medical oncologist
Tier 3
Dr. Yuki Quinn
Thoracic medical oncologist
Tier 2
Dr. Tomoko Ueda
Pathologist
Tier 2
Dr. Ximena Rossi
Radiation oncologist
Tier 1
Dr. Benedikt Ivanova
Oncology pharmacist
Tier 2
Dr. Chloé Dubois
Pathologist
Tier 3
Dr. Farah Jensen
Primary care physician
Tier 1
Dr. Ximena Bauer
General neurologist
Tier 3
Dr. Andrea Fischer
General neurologist
Tier 2